Laboratorio Reig Jofre, S.A (RJF) Fair Value & Analysis
Healthcare · ES · Market cap €220M
Fair value as of: Jun 24, 2026
From 17 valuation models · updated 5 days ago
Share price −1.5% over the past month.
Price vs Fair Value (12 months)
12‑month range €2.36 – €3.24 · fair‑value band €1.02 – €1.58 · the €2.71 price screens above the €1.36 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Laboratorio Reig Jofre, S.A (RJF) currently trades at €2.71, while our model-based Fair Value estimate is €1.36 — implying the stock looks roughly 49.8% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Laboratorio Reig Jofre, S.A generated revenue of €335M at a net margin of 1.3%. Revenue declined 1.9% year over year. It earns a return on equity of 2.0%. Net debt stands at €88.0M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmaceuticals, food, and other products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women's health; and food supplements under the Forté Pharma brand. In addition, the company provides CDMO and CMO services; and management and administration services. It sells its products through business partners. The company was founded in 1929 and is headquartered in Barcelona, Spain. Laboratorio Reig Jofre, S.A. operates as a subsidiary of Reig Jofre Investments SL.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Laboratorio Reig Jofre, S.A reported revenue of €331M in FY2025 versus €236M in FY2021, a compound +8.8%/yr. Reported net income was €5.0M in FY2025, compounding −0.4%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Laboratorio Reig Jofre, S.A (RJF) undervalued?
What is the fair value of RJF?
What is the quality score of RJF?
What is the revenue of Laboratorio Reig Jofre, S.A (RJF)?
What is the net profit margin of RJF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.